SecBot SecBot
SECBOTREPLAY Home › Report › JAGX

JAGX · Q3 revenue -24% YoY

Jaguar Health, Inc. · 8-K filed Nov 16, 2026 at 09:15 ET

At the news

BEARISHIMPACT 6/10

8-K filed Nov 16, 2026 at 09:15 ET

Jaguar Health reported Q3 2026 total revenue of $2.3M, down 24% YoY from $3.1M, driven by an 82% decline in product revenue to $0.55M after licensing U.S. commercial rights to Future Pak. Net loss narrowed 40% to $5.8M from $9.6M, and the company reduced debt by $10.1M via a stock-for-debt exchange with Streeterville. A planned NDA filing for crofelemer in MVID in mid-2027 provides a long-term catalyst, but the revenue decline and extreme dilution risk from a $75M ATM program (15x market cap) dominate the near-term outlook.

  • Total revenue fell 24% YoY to $2.3M in Q3 2026 from $3.1M
  • Product revenue dropped 82% YoY to $0.55M after licensing Mytesi/Canalevia to Future Pak
  • Net loss narrowed 40% to $5.8M from $9.6M
  • Debt reduced by $10.1M via stock-for-debt exchange with Streeterville

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access